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ABS TR AC T VII 
Abstract 
Immunotherapies including checkpoint blockade and adoptive T cell 
transfer (ACT) show great promise for the treatment of melanoma, with 
long-term effects in some patients. However, around half of the patients 
with metastatic malignant melanoma will not be cured with available 
therapies today, and these patients require other treatment strategies. For 
metastatic uveal melanoma (a rare melanoma of the eye), available 
immunotherapies are less effective, and there is currently no approved 
therapy for these patients. 
To be able to study immunotherapies in mice, we in Paper I developed 
an immune-humanized mouse model called patient-derived xenograft 
(PDX) version 2 (PDXv2). In this model, tumor cells and tumor infiltrating 
lymphocytes (TILs) from the same patient were grafted in IL-2 transgenic 
NOD/SCID IL2 receptor gamma knockout (NOG) mice, and we found that 
responses in the mouse model correlated to responses in the corresponding 
patients in a clinical trial of ACT.  
So far, no chimeric antigen receptor T cell (CAR-T) therapy is 
approved for use in solid tumors. In Paper II we tested the potential for 
CAR-T therapy in melanoma. First, we used TCGA to determine the 
expression in melanoma biopsies of targets for commercially available 
CAR-T cells. We found that HER2 is expressed in both cutaneous and 
uveal melanoma biopsies. HER2 CAR-T cells were then used to treat skin 
melanoma and uveal melanoma patient-derived xenografts in the PDXv2 
mouse model resulting in curative responses, even in models resistant to 
TIL therapy. However, CAR-T cells were only effective in IL-2 transgenic 
mice and not in regular NOG mice.  
In order to facilitate translation of the findings from Paper II into a 
treatment strategy for patients with melanoma, we developed CAR-
expressing autologous TILs (called CAR-TILs). In Paper III, we 
demonstrate that this strategy could overcome resistance to treatment with 
autologous TILs in melanoma. Current CAR-T therapies use blood-derived 
T cells as a substrate for CAR-T cell production. We hypothesized that by 
using TILs instead, we might facilitate homing to the tumor and potentially 
also utilize the fact that some TILs can recognize melanoma antigens, 
enabling a dual targeting of CAR-TILs. We also developed an automated 
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production protocol for TILs and CAR-TILs utilizing a bioreactor, 
enabling safe and less variable production of the drug product. 
Keywords 
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SAM M AN FATTNING PÅ SVENSKA IX 
Sammanfattning på svenska 
Immunterapi är en grupp behandlingsmetoder som syftar till att aktivera 
patientens egna immunförsvar för att döda cancerceller. I hudmelanom har 
denna typ av terapier, framför allt antikroppsbaserade (så kallade 
checkpoint blockad) och cellbaserade metoder (adoptiv T-cellstransfer; 
ACT) visat sig kunna ge långvariga effekter hos många patienter. 
Dessvärre svarar inte alla patienter med hudmelanom på denna typ av 
behandling, varför nya behandlingsmetoder behöver utvecklas. Uvealt 
melanom uppkommer i ögat och vid spridd sjukdom är den mycket 
svårbehandlad. För denna patientgrupp är överlevnaden låg och dagens 
behandlingsmetoder fungerar ej.   
 I syfte att kunna studera immunterapi i möss utvecklade vi i delarbete I 
en ny typ av immun-humaniserad musmodell, som vi kallar patient-
deriverade xenograft version 2 (PDXv2). I denna musmodell används 
immunkomprimerade möss som överuttrycker humant IL-2, vilket leder till 
att både humana cancerceller och humana immunceller (så kallade tumör-
infiltrerande lymfocyter; TIL) från samma patient med kutant melanom 
kan transplanteras till mössen. Denna metod är en modell av ACT, och vi 
har visat att då tumör och TIL kommer från en patient som svarar på ACT i 
kliniken, så dödas även tumören i mössen. Då cellerna däremot kommer 
från en patient som inte svarade på ACT i kliniken så svarar heller inte 
mössen på behandlingen. Detta visar att PDXv2 kan användas för att 
studera immunterapi i melanom, och ger oss ett verktyg för forskning som 
syftar till att förbättra och förnya immunterapi mot melanom. 
CAR-T är en typ av immunterapi som fungerar väldigt bra i patienter 
med blodcancer, men som än så länge inte är en godkänd behandling för 
patienter med solid cancer. I delarbete II studerade vi CAR-T behandling i 
PDXv2 och fann att CAR-T celler som känner igen HER2 effektivt dödade 
svårbehandlade melanom i mössen, inklusive både hudmelanom som inte 
svarade på ACT och uveala melanom. 
I delarbete III utvecklade vi en ny behandlingsmetod som kombinerar 
ACT med TIL och CAR-T (så kallad CAR-TIL) och visade att denna 
metod kan övervinna resistens mot ACT med TIL i melanom. Detta 
tillvägagångssätt utnyttjar fördelar med både ACT och CAR-T, genom två 
olika sätt att döda cancerceller. Vi utvecklade också en automatiserad 
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metod för att producera CAR-TIL i en bioreaktor, för att göra 
tillverkningen säkrare och mer standardiserad. 
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1 .  INTR ODUC TION 1 
1. Introduction 
1.1 Cancer 
Cancer is a group of diseases arising due to uncontrolled growth of genetically 
alterered, malignant cells. The development of cancer is a complex and step-wise 
line of events altering the regulation of normal cells in the body. Normal cells 
are tightly controlled when it comes to growth and survival. Cancer cells, 
however, have mutations in their genetic material (DNA) to achieve uncontrolled 
growth and deregulation of cell death. In order for cancer to develop, several 
capabilities are required of the cancer cell. These capabilities are commonly 
referred to as The Hallmarks of Cancer, and include: sustaining proliferative 
signaling, evading growth supressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis [1]. More 
recently, two additional hallmarks have been suggested: reprogramming of 
energy metabolism and evading immune destruction [2]. 
 Cancer can develop in any tissue but with different likelihood. Most often, 
cancer develops in epithelial cells (called carcinoma). Epithelial cells are located 
in the skin and in tissues lining internal organs and body cavities. Cancer can alo 
develop in connective and supportive tissues (for example bone, muscle, fat and 
blood vessels; called sarcoma) or in blood cells of the immune system (called 
lymphoma and leukemia).  
 The development of cancer is mainly caused by genetic misfortune owing 
to the propensity of cell division and DNA replication to spontaneously go 
wrong. Since these events happen rarely, cancer is more common in older 
individuals. However, there are several things that increase the probability of 
cancer development, including genetic pre-dispositions and some environmental 
factors such as smoking and exposure to UV-radiation or chemicals. Even 
though our knowledge and management of cancer has improved over recent 
years, the total number of people affected is increasing [3], and we need to 
advance our therapeutic strategies further to battle cancer.  
     2 
1.1.1. Cancer metastasis 
Cancers have the ability to dessiminate from the primary site (the tissue from 
where the cancer originated) to distant sites of the body, a process called 
metastatic spread. This is in contrast to benign tumors that do not possess or 
have not yet developed this property. Metastasis is the leading cause of cancer 
mortality [4]. Cancer is often classified according to the spread of disease, from 
phase I/II (localized to the primary site) to phase III (lymphatic spread) and 
finally to stage IV (distant metastases) [5]. In general, the earlier the stage at 
which a cancer is discovered, the better the prognosis.         
1.1.2. The immune system in cancer 
The immune system seems to play a vital role in surveilling the body for 
alterations in cellular behavour, including malignant transformation of normal 
cells into cancer cells. Evidence for immunosurveillance include the fact that 
immunocompromised individuals (including people receiving organ transplants 
and HIV patients) have a slightly higher incidence of cancer compared to healthy 
controls [6-11]. Second, immune cells are found at the tumor-site and can 
recognize tumor-assiciated antigens (TAA) [12]. In many tumor-types, 
infiltration of immune cells (lymphocytes) in the tumor is correlated to good 
prognosis [13-16]. There is also evidence showing that mice lacking different 
components of the immune-system more frequently develop tumors compared to 
immune-competent mice [17-21].  
Even though the immune system can recognize and eliminate cancer cells, 
there are ways for the cancer cell to evade immunity, which results in the 
formation of clinically evident tumors. The complex interactions between the 
immune system and developing tumors (called immunoediting) can be summed 
up by three processes: Elimination, Equilibrium and Escape [22]. The 
Elimination phase corresponds to immunosurveillence, including recognition 
and elimination of tumor cells by the immune system. During Equilibrium, 
tumor cells that managed to survive Eliminiation experience immune selection, 
favoring the development of clones resistant to immune attack. The last phase of 
immunoediting is called Escape, when tumor cells manage to escape control of 
the immune system, leading to tumor formation. Cancer cells have different 
strategies to escape the immune system. Some of these evasion mechanisms can 
be overcome by immunotherapy, a group of treatment strategies aiming to 
activate the patients own immune system to fight off cancer. 
1 .  INTR ODUC TION 3 
1.1.2.1 Organization of the immune system 
The immune system is comprised of many different cell types with the general 
purpose to defend our body against foreign and intrinsic threats such as 
pathogens and cancer cells. Broadly, the immune system can be divided into 
innate immunity and adaptive immunity. Innate immunity provides quick and 
unspecific defences. It is comprised by cellular and biochemical defences, 
present at all times in healthy individuals. Upon detection of a threat, the innate 
immune system can subsequently stimulate adaptive immunity [23]. The 
adaptive immune system consists of lymphocytes and their products, and can 
also use and enhance effector mechanisms of the innate immune system. 
Adaptive immunity is specific to the current threat, and has the ability to induce 
immunogenic memory. 
1.1.2.2 Innate immunity 
Innate immunity consists of primitive defences including: 
 
o Physical and chemical barriers (epithelial cells and antimicrobial 
substances produced by the same) 
o Innate immune cells: granulocytes, phagocytes and NK cells 
o The complement system (blood proteins) 
o Cytokines (regulate and coordinate the activity of immune cells) 
 
Innate immunity is highly conserved in animals and plants, and all multicellular 
organisms have innate immunity [24]. Innate immunity is an instant first-line of 
defence protecting the body against infectious agents, while the induction of 
adaptive immunity takes longer to develop and would give infectious agents too 
much time to replicate. Epithelial surfaces act as physical barriers protecting 
against pathogens, including the skin and mucosal tissues. If pathogens manage 
to break this barrier, innate immune cells in blood and tissues wait to defend the 
body against the intruder. Blood also contains proteins called the complement 
system, with the purpose to bind to conserved structures on pathogens. 
Complement proteins can induce pore-formation in bacterial membrane inducing 
cell lysis, as well as bind to pathogens and attract immune cells (phagocytes) 
[25]. 
 Phagocytes are innate immune cells capable of ingesting (phagocytosing) 
bacteria, including neutrophils, mast cells, macrophages and dendritic cells. 
Phagocytes identify their target cells by recognition of pathogen-associated 
molecular patterns (PAMPs) or by coating by complement proteins or 
     4 
antibodies. PAMPs are evolutionary conserved structures on pathogens 
including for example bacterial lipids and double-stranded RNA found in some 
viruses [26]. 
Some cells of the innate immune system contain intracellular granules 
containig proinflammatory molecules and effector molecules capable of killing 
pathogens [27]. These cells are called granulocytes and include neutrophils, mast 
cells, eosinophils and basophils. 
NK cells can recognize virus-infected cells and kill them by secreting 
molecules and proteins capable of lysing the target cell. NK cell recognition is 
mediated by receptors recognizing MHC I (KIR), stress receptors MICA/B 
(NKG2D) and bound antibodies on the target cell [28]. NK cells have also been 
shown to play a role in the detection and control of cancer cells. Cancer cells can 
downregulate MHC I or the antigen presentation pathway, as one way to evade 
immune recognition. NK cells recognize a lack of MHC I on their cell surface, 
for example pathogens or cancer cells downregulating MHC I. This is called the 
“missing self” hypothesis [29].  
1.1.2.3 Adaptive immunity 
Adaptive immunity consists of lymphocytes, and can be further divided into 
humoral immunity (B-lymphocytes and their antibody products), and cell-
mediated immunity (T-lymphocytes). Adaptive immunity is specific to variable 
elements called antigens. The adaptive immune response is initiated when 
phagocytes engulf pathogens or abnormal cells, alternatively take up soluble 
antigens, and present these antigens on MHC II, representing a link between 
innate and adaptive immunity [30]. Cells with this ability are called antigen 
presenting cells (APCs) and include dendritic cells (DCs), B cells, macrophages 
and monocytes. Conventional DCs are the most efficient APC in terms of 
antigen uptake, presentation and activation of T cells [31]. APCs are specialized 
to present antigens to CD4+ T cells on MHC II, but can also present antigens on 
MHC I to CD8+ T cells (so called cross-presentation) [32]. 
T cells mature in the thymus, and can recognize antigens via their T cell 
receptor. T cells are generally categorized into T helper cells (CD4+) and 
cytotoxic T cells (CD8+). T helper cells produce cytokines and thereby “help” 
other cells of the immune system to perform their function, including cytotoxic 
T cells [33]. Another group of CD4+ T cells are regulatory T cells, able to 
suppress an immune-response and playing an important role in maintaining self-
tolerance, preventing autoimmune disease [34]. Cytotoxic T cells induce lysis of 
altered cells upon activation, such as virus-infected cells or cancer cells [35]. 
1 .  INTR ODUC TION 5 
The interactions between T cells and cancer cells will be more thoroughly 
discussed in the upcoming sections. 
B cells develop in the bone marrow, and can be activated by recognition of its 
cognate antigen by the B cell receptor [36]. In response to activation, B cells 
mature into plasma cells capable of producing antibodies that can neutralize 
pathogens, inhibiting them from infecting human cells. Antibody binding to 
pathogens can also activate other componenents of the immune system by 
facilitating phagocytosis and cytotoxicity. Humoral immunity is efficient in 
eliminating free virus and bacteria, but cannot efficiently target intracellular 
threats, as in the case for virus-infected cells or cancer cells.  
Both B and T lymphocytes are able to proliferate in response to antigen 
recognition, thus producing large clonal armys recognizing a specific threat. 
Importantly, activated lymphocytes can also develop into long-lived memory 
cells [37, 38]. This property results in immunological memory, enabling a 
quicker and more efficient immune response upon re-encounter of the same 
threat.  
1.1.2.4 Immune recognition of tumor cells by T cells 
In general, cancer cell recognition by the immune system is based on antigen 
presentation on receptor complexes called MHC I. All cells in the body have 
MHC class I, consisting of one alpha chain (encoded by the HLA A/B/C genes 
in humans) and one β-2-microglobulin chain (encoded by the B2M gene). MHC 
I present cellular antigens on the cell surface which can be recognized by 
cytotoxic (CD8+) T cells via their T cell receptor (TCR) (Figure 1 (b)) [39]. 
Antigens are protein fragments (peptides) produced in the proteasome by 
breakdown of a fraction of all synthesized proteins in the cell. The antigens are 
subsequently transported to the endoplasmatic reticulum (ER) and loaded onto 
MHC I complexes. The loaded MHC I complexes are then transported to the cell 
surface via vesicles, where they display fragments of the proteins synthesized 
within the cell to the immune system [40]. Genetically altered cells can be 
detected by the immune system via presentation of mutated antigens on MHC I 
to cytotoxic T cells. 
In order for a cytotoxic T cell to become activated, three different signals are 
required [41]. The first signal is mediated by MHC I and bound antigen 
recognized by the TCR. Additionally, co-stimulatory receptors CD80 and CD86 
on the target cell bind CD28 on the T cell, mediating a second signal. Finally, 
Interleukin 2 (IL-2), a cytokine produced by activated helper (CD4+) T cells is 
required for subsequent clonal expansion of the activated T cell. 
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Once the primed cytotoxic T cell encounter an altered cell presenting it´s 
cognate antigen, it is activated to degranulate and release cytotoxic substances 
targeting the target cell, including perforins, granzymes and gamma-interferon 
(IFN-γ). Perforins create pores in the plasma membrane of target cells, allowing 
for passive diffusion of granzymes, which in turn cleave and activate pro-
apoptotic caspases. Cytotoxic lymphocytes can also kill target cells by another 
mechanism, mediated by the Fas death receptor on tumor cells [42]. Fas ligand 
(FasL) on cytotoxic T cells can bind the Fas receptor, inducing apoptosis of the 
target cell. 
Downregulation of the antigen presentation pathway by cancer cells disable T 
cell recognition, representing an important immune evasion strategy. In addition, 
inhibitory receptors on cancer cells can bind to and inactivate cytotoxic T cells. 
These and other mechanisms to evade immunity are presented in the next 
section. 
1.1.2.5 Immune evasion    
In order for cancer to develop, cancer cells need to evade immune destruction, 
representing one of the hallmarks of cancer [2]. Many different mechanisms of 
immune evasion have been described, including hiding strategies, immune 
regulation and resistance to immune cell killing.  
One obvious way for the cancer cell to evade detection by the immune 
system is to downregulate the antigen presentation machinery (hiding). 
Strategies to do so include downregulation of tumor-associated antigens, MHC I 
genes (HLA-A/B/C and B2M) or other proteins involved in the transportation of 
MHC I complexes to the cell surface (for example TAP1/2) [43, 44]. However, 
complete lack of MHC I expression can cause NK-cell mediated killing, and 
therefore tumor cells might selectively downregulate some but not all MHC I 
molecules to decrease expression of specific antigens [45]. 
Another strategy for tumor cells to evade immunity is to inhibit T cell 
function. This can be done in several ways. Checkpoints on T cells (including 
Cytotoxic T Lymphocyte Antigen-4; CTLA4 and Programmed Cell Death 
Protein 1; PD1) negatively regulate their activity. CTLA4 bind CD80/CD86 
(also known as B7-1/B7-2), the same ligands that bind CD28 mediating the 
second signal required for T cell activation [46]. PD1 is another checkpoint on T 
cells that bind PDL1 on tumor cells, aslo resulting in inhibition of T cell 
function. Upregulation of PDL1 can be adopted by cancer cells as a way to 
evade T cell mediated killing [47]. 
1 .  INTR ODUC TION 7 
Cancer cells also have additional strategies to regulate the immune system. 
They can for example attract regulatory immune cells to the tumor site, including 
regulatory T cells (Tregs) or myeloid-derived suppressor cells that in turn inhibit 
the activation of cytotoxic T cells. Treg inhibition can be achieved in several 
ways, including production of inhibitory cytokines or cytotoxic granzyme B, 
inhibition of DC function, checkpoint expression or by binding all available IL2 
with high affinity receptors, depriving other T cells of necessary IL2 stimulation 
[48]. Tregs normally inhibit CD8+ T cells in tissue, and a lack of Tregs lead to 
development of autoimmune disease [34]. Cancer cells can also produce 
immune-inhibitory molecules such as IL-10 and TGF-β [49], and induce 
lymphocyte apoptosis by secreting soluble FasL [50]. 
Finally, cancer cells can become insensitive to T cell induced apoptosis, for 
example by inhibiting the caspase cascade or acquire resistance to FasL-
mediated killing [51]. 
1.2 Immunotherapeutic strategies 
Cancer immunotherapy is a group of therapeutic strategies aiming at activating 
the patient’s own immune system to achieve tumor eradication. This can be done 
in several ways, and the main approaches are described below. 
1.2.1. Immune system modulators  
Immune system modulators are a group of treatment strategies that act by a 
general immune stimulation, in order to boost an already existing immune 
response against the tumor.  
Interleukin 2 (IL2) is the T cell growth factor, required for activation and 
clonal expansion of T cells. High dose bolus IL2 have been approved for use in 
patients with renal cell carcinoma [52] as well as melanoma [53]. In a small 
fraction of patients, this treatment leads to tumor shrinkage and long-term 
survival. Toxicities included cardiopulmonary toxicities but was most often 
reversible [54]. 
Interferon α (IFN-α) is another molecule that can stimulate immune responses 
in some patients with renal cell carcinoma [55], but is also associated with low 
response rates and toxicities, limiting the usefulness of this treatment. In 
melanoma, IFN-α treatment did not improve the patient outcome [56] 
     8 
Bacillus Calmette-Guérin (BCG) is a weakened form of Mycobacterium 
bovis virus, which can be used to successfully induce immune responses in 
patients with bladder cancer [57].  
1.2.2. Cancer vaccines 
Cancer vaccines can be either prophylactic or therapeutic. The first act in the 
same way as other vaccines, that is to produce an immune response against a 
weakened virus or viral antigen, and hence only work in virus-induced cancers. 
One example is human papilloma virus (HPV) vaccine which is successfully 
used to prevent the development of cervical cancer [58]. 
In the case for non-viral-induced cancer, other types of vaccination 
approaches are required, and these treatments are used in patients with already 
existing lesions. Great efforts have been made to develop therapeutic vaccines 
against cancer, largely with modest success. Early studies using free peptides 
suffered from lack of immunization, resulting in no or low therapeutic benefit 
[59].  
In order to improve immunization in cancer vaccines, dendritic cell-based 
vaccines have been developed [60]. So far, the most promising results for this 
approach has been achieved in prostate cancer with sipuleucel-T, a vaccine 
comprised by autologous peripheral blood mononuclear cells cultured in vitro 
with a fusion protein composed of PAP (prostatic acid phosphatase; a prostate 
tumor associated antigen) and GM-SCF (Granulocyte-macrophage colony-
stimulating factor, a cytokine). Sipuleucel-T caused a survival benefit of about 4 
months in patients with metastatic, castration-resistant prostate cancer [61]. 
1.2.3. Oncolytic viruses 
Oncolytic viruses work by infecting and causing lysis of tumor cells, while 
largely sparing normal cells. Many different strains of oncolytic viruses exists 
that are currently under pre-clinical and clinical investigation, often based on 
adenoviruses or herpes simplex viruses genetically altered to optimize safety and 
tumor cell tropism [62].  
So far, this type of treatment has been approved for use in patients with head 
and neck cancer (called H101, based on adenovirus) [63] and melanoma (called 
T-VEC, based on herpes simplex virus) [64]. These viruses are administered via 
intra-tumoral injections, and can cause tumor shrinkage especially in the injected 
lesions but also in non-injected lesions [65]. Treatment with oncolytic viruses 
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are generally well tolerated, but the major challenge with this treatment strategy 
is to induce a systemic immune response required for effects on patient survival 
[66]. 
1.2.4. Antibody based immunotherapy 
Antibody-based immunotherapies can be divided into two types; tumor targeting 
antibodies and checkpoint inhibitors. 
1.2.4.1 Tumor targeting antibodies  
Monoclonal antibodies targeting cancer-associated proteins have been approved 
for treatment of several malignancies. They work by opsonizing (coating) cancer 
cells, leading to activation of an immune response. Several mechanisms for 
immune activation by monoclonal antibodies have been revealed, including 
antibody-dependent cellular cytotoxicity (ADCC), complement-dependent 
cytotoxicity (CDC) and the induction of adaptive immune responses [67]. 
ADCC typically involves NK cells, which recognize the constant (Fc) portion of 
an antibody via their Fc receptor (CD16) leading to activation and release of 
cytotoxic substances including perforin and granzymes. CDC depends on 
complement proteins binding to the antibodies and initiating a cascade leading to 
cellular lysis. Monoclonal antibodies can also activate the adaptive immune 
system, since peptides derived from lysed tumor cells (for example through 
ADCC or CDC) can be loaded onto MHC II and MHC I (via so called cross-
presentation) on DCs, leading to T cell activation. 
 There are several tumor targeting antibodies approved for use in cancer 
patients, which increase survival in some patient groups. These include HER2 
antibodies used for HER2 positive breast cancer [68, 69], CD20 antibodies used 
in B cell malignancies [70-72] and EGFR antibodies used in colorectal cancer 
[73, 74]. 
1.2.4.2 Checkpoint blockade 
Checkpoint inhibitors are antibodies that bind to and inhibit inhibitory molecules 
(so called checkpoints) on T cells, and hence enable the T cell to become 
activated and attack cancer cells. Several checkpoints have been discovered. 
Inhibitors against CTLA4 [75, 76] and PD1 [77, 78] can lead to durable cancer 
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regression and increased survival, and have been approved for use in patients 
with melanoma. PD1 inhibitors are also efficacious in other cancer types, 
including non-small cell lung cancer (NSCLC) and renal cell carcinoma [79, 80]. 
 A number of other checkpoints have been described and novel inhibitors are 
being evaluated preclinically; including (but not limited to) LAG-3 [81], TIM-3 
[82], TIGIT [83] and Siglec-15 [84]. 
1.2.5. Cell based immunotherapy 
Cell based immunotherapy utilizes tumor reactive T cells, which can be 
expanded and activated in vitro before infusion at large numbers to the patient.  
These tumour-specific T cells can be derived from the tumour environment, 
called tumour-infiltrating lymphocytes (TILs), or from peripheral blood. They 
can also be modified to express high affinity antitumour T cell receptors (TCR) 
or genetically engineered chimeric antigen receptors (CAR) with the aim to 
improve their anti-cancer activity. 
1.2.5.1 Adoptive T cell transfer 
Adoptive T cell transfer (ACT) utilizes the anti-cancer properties of T cells 
found in the tumor, so called tumor-infiltrating lymphocytes (TILs). By 
extracting TILs from human tumors, expanding them in vitro to large number in 
the presence of the T cell growth factor IL-2 and finally infusion of the cellular 
product back into the same patient, tumor-specific T cells can be reactivated and 
mount an attack on the tumor. ACT was the first cell-based therapy successfully 
used in the clinic, and this approach show great efficacy in about 50% of patients 
with cutaneous melanoma [85, 86]. 
Approaches have also been used to determine the tumor antigen specificity of 
transferred T cells. In melanoma, Melanoma antigen by T cells 1 (MART1) and 
GP100 specific T cells have been used for adoptive transfer [87, 88]. In patients 
with melanoma and synovial cell sarcoma, Cancer/testis antigen 1 (also known 
as NY-ESO-1) specific T cells have been used [89]. So far, these therapies are 
generally not more efficacious compared to ACT with a pool of TILs (with 
unknown TCR specificity) but instead correlated to more serious adverse events.  
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1.2.5.2 CAR-T 
Another approach to cause T cell mediated killing in cancer patients is to equip 
blood-derived T cells with a chimeric antigen receptor (CAR). A CAR-receptor 
is a genetically modified receptor consisting of a binding moiety and T cell 
activating components including the intracellular part of CD3 and co-stimulatory 
molecules [90]. The binding domain is a single-chain variable region from a 
monoclonal antibody with the potential to bind to a specific surface protein of 
the target cell (Figure 1 (a)). The signaling domain in the first generation of 
CAR receptors including the CD3z intracellular signaling domain [91]. Later, 
the functional properties of CARs have been further optimized by including co-
stimulatory domains, most often either CD28 or 4-1BB (in second generation 
CARs) or a combination of both (in third generation CARs). A fourth generation 
of CARs have also been generated by adding IL-12 to the base of the second-
generation constructs, known as T cell redirected for universal cytokine-
mediated killing (TRUCKs) [92].  
The most encouraging results for this treatment strategy are the successes 
achieved with the use of CD19 CAR-T cells in adult and pediatric patients with 
B cell malignancies [93, 94]. A majority of patients with B cell lymphoma and 
leukemia respond to CD19 CAR-T treatment, often resulting in durable 
remissions, leading to approval of these treatments. However, adverse events in 
CAR-T treatments are frequent, and include cytokine release syndrome (CRS) 
and neurological toxicities. These adverse events can be severe and lead to 
hospitalization. Most often they are managed with immunosuppressive 
treatment, but can sometimes be fatal. 
A few CAR-T cell therapies have also been used in patients with other 
malignancies, including solid cancers. CEA CAR-T therapy has been tested in 
patients with gastrointestinal cancers [95, 96], MUC16 CAR-T therapy in 
ovarian cancer [97],  MUC1 CAR-T therapy for seminal vesicle cancer [98] and 
GD2 CAR-T therapy in patients with neuroblastoma [99]. HER2 CAR-T therapy 
has been evaluated in patients with HER2 positive sarcoma [100], glioblastoma 
[101] and biliary tract cancer and pancreatic cancer [102]. Approaches to treat 
solid tumors with CAR-T therapy have so far been much less impressive 
compared to CD19 CAR-T treatment for B cell malignancies. Important 
challenges need to be overcome in order to be able to use CAR-T therapy 
successfully in patients with solid tumors. These include finding appropriate 
CAR targets, achieving CAR-T cell tumor penetration and sustaining persistence 
and cytotoxicity in the hostile tumor microenvironment [103]. 
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Figure 1. Tumor cell recognition by chimeric antigen receptor (CAR) T cells (a) and T cell receptor 
(TCR) mediated T cells recognition (b). The CAR is comprised by a single chain antibody domain 
(scFv) recognizing native proteins on the tumor cell surface, linked by a hinge and transmembrane 
domains to several intracellular signaling domains. The TCR instead recognizes antigen peptides, 
processed by the proteasome, loaded onto MHC I protein complexes, and transported to the tumor 
cell surface. Adapted and modified from [104]. 
1.3 Cutaneous (skin) melanoma 
Melanoma (also called malignant melanoma) is a cancer arising from 
melanocytes. Melanocytes are melanin-producing cells found mainly in the skin, 
but also in other tissues such as the uvea of the eye, in mucosal tissues and in the 
leptomeninges. Melanoma arising in the skin is called cutaneous melanoma. 
Cutaneous melanoma is the deadliest form of skin cancer. 
1.3.1 Normal melanocytes 
Melanocytes are derived from the neural crest, and migrate to the skin and other 
sites of the body during embryonic development [105]. Melanocytes in the skin 
have the function to produce melanin in order to protect underlying 
(subcutaneous) cells from UV-damage from sun-exposure. UV-radiation cause 
melanocytes to produce melanin [106], a process called melanogenesis.  
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1.3.2 Epidemiology 
Melanoma affects mainly the Caucasian population, and the incidence is 
increasing worldwide [3]. Also in Sweden, the incidence has increased over the 
last decades, and affects about 4000 people yearly [107]. 
1.3.3 Etiology 
The most important risk factors for cutaneous melanoma include fair skin and 
concomitant sun exposure. UV radiation from the sun can cause DNA-damage 
leading to mutations, increasing the risk of cancer development. Melanomas 
frequently show UV signature mutations with frequent C→T transitions at 
dipyrimidine sites [108]. Frequent genetic alterations important for development 
of melanoma are summarized in Figure 2. 
Cutaneous melanoma commonly harbor mutations in V-Raf Murine Sarcoma 
Viral Oncogene Homolog B (BRAF, 66% of patients) [109] or Rat Sarcoma N 
(N-RAS, 20% of patients) [108], causing mitogen-activating protein kinase 
(MAPK) pathway activation. Activation of the MAPK pathway leads to 
increased proliferation and survival in melanoma cells [110, 111]. 
BRAF is a serine/threonine protein kinase activating the MAPK pathway by 
phosphorylation of another kinase (mitogen-activated protein kinase kinase; 
MEK), which in turn phosphorylates and activates extracellular signal-regulated 
kinase (ERK). ERK can phosphorylate many different proteins including 
transcription factors such as c-myc [112]. BRAF mutations most commonly 
occur in V600E, causing constitutive activation of the kinase as well as 
insensitivity to negative feedback mechanisms [109].  
N-RAS is a GTPase upstream of BRAF. Most commonly, mutations in 
melanoma cells occur at Q61 and disrupt the GTPase activity of N-RAS, locking 
it in its active conformation [113].  
KIT mutations are found in some subtypes of melanomas, including mucosal, 
acral and melanoma on chronic sun-damaged skin [114]. 
Cutaneous melanomas frequently also have mutations in tumor suppressor 
genes including CDKN2A, P53 and PTEN [115]. PTEN loss in turn lead to 
upregulation of the PI3K-AKT pathway, also involved in increased proliferation 
and migration of melanoma cells [116]. 
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1.3.4 Clinical classifications and prognosis 
In cutaneous melanoma, the stage at which the cancer is detected has great 
importance for the prognosis of the patient [117]. About 90% of melanomas are 
detected as primary tumors, and these patients have a good 10-year survival rate 
of 75-85% [118]. 
In contrast, metastatic melanoma (stage IV) historically had a dismal 
prognosis, but the outcome for these patients has significantly improved over 
recent years with the development of targeted therapies and immunotherapies 
[117]. 
1.3.5 Treatment options 
1.3.5.1 Surgery 
Primary cutaneous melanomas can be surgically removed with good outcome 
[118]. This is a curative treatment when the primary tumor has not yet spread to 
other sites (metastasized). However, metastatic disease requires additional 
treatment strategies. Options include chemotherapy, targeted therapy and 
immunotherapy. 
1.3.5.2 Chemotherapy 
Dacarbazin is approved for treatment of metastatic cutaneous melanoma, and 
was for many years the only approved therapy. Response rates of 15-20% have 
been reported but no survival benefit [119]. Dacarbazin is often used in 
combination with carboplatin. Other drugs used historically or at relapse 
following other treatments include taxanes. 
Isolated limb perfusion is a localized chemotherapy treatment possible when 
melanoma metastases are confined to a limb. Response rates in clinical trials are 
very good, around 90%,  however a survival benefit has not been established 
[120]. 
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1.3.5.3 Targeted therapy 
BRAF inhibitors have been approved for use in patients with BRAF mutated 
melanoma, including Dabrafenib [121] and Vemurafenib [122]. High response 
rates of about 50% are achieved with BRAF targeted treatment. 
For N-RAS mutated melanoma, no inhibitor targeting N-RAS directly has 
been developed. However, MEK, a protein kinase downstream of both N-RAS 
and BRAF has been targeted with the MEK1/2 inhibitor Trametinib [123]. 
Response rates to Trametinib are 28%. 
Especially good clinical outcome for patients with BRAF mutated melanoma 
was achieved by combining BRAF and MEK inhibitors [124], leading to an 
impressive response rate of 67% for patients with BRAF mutated melanoma.  
Pre-clinical research also indicate a possibility to target ERK, downstream of 
MEK, in combination with BRAF and MEK to further lower the fitness 
threshold for melanoma cells in PDX mice [125]. The ERK inhibitor Ulixertinib 
has been tested in a phase I clinical trial and was shown to induce partial 
responses in some patients [126]. 
In conclusion, targeted therapies have very good response rates in cutaneous 
melanoma and increase survival in patients, but there is a problem of 
development of resistance in most treated patients [127].  
1.3.5.4 Immunotherapy 
Cutaneous melanoma is the disease where immunotherapy has been researched 
and tested for the longest time. In this disease, lymphocyte infiltration is 
correlated to good prognosis [128, 129], and a high mutational burden also 
suggests high immunogenicity [130]. Several immunotherapies tested thus far 
has had limited effects on survival, including IL-2, vaccines, interferons and 
histamine [59]. T-Vec (Talimogene Laherparepvec) is an oncolytic virus that 
increased survival in patients with melanoma with about 4 months [65]. So far, 
the most promising approaches have been antibody based (checkpoint inhibitors) 
[131-133] or cell based (adoptive T cell transfer; ACT) [86].  
Immune checkpoint activation is one way for tumor cells to evade immunity 
and checkpoint blockade overcome negative regulation of T cell function [134-
137]. Immunotherapy using checkpoint inhibitors targeting CTLA4 and PD1 
have been approved for use in patients with cutaneous melanoma. The CTLA4 
inhibitor Ipilimumab achieved an objective response rate of 60%, and could 
increase the survival of patients [75]. Importantly, this was the first therapy to 
increase survival in patients with metastatic melanoma. PD1 inhibitors have also 
been developed and approved for treatment of metastatic melanoma, including 
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Pembrolizumab [77] and Nivolumab [78]. PD1 inhibitors show better response 
rates compared to Ipilimumab, and less side effects [131]. A combination of 
CTLA4 (Ipilimumab) and PD1 blockade (Nivolumab) has even higher effect, but 
also more severe side effects compared to monotherapies [132, 133]. 
Importantly, immunotherapy with checkpoint inhibitors can induce long-term 
responses in patients with metastatic melanoma. 
Adoptive T cell transfer (ACT) is another immunotherapeutic strategy tested 
in patients with cutaneous metastatic melanoma in clinical trials, showing 
responses in about 50% of patients [85, 86, 138]. In 20% of all patients, 
responses are even durable [85]. 
In conclusion, long-term follow-up indicates that immunotherapies can cause 
durable responses in patients with metastatic melanoma. However, not all 
patients will be cured with available immunotherapies today, pointing to the 
need of developing additional strategies. 
1.4 Uveal melanoma 
Melanoma arising in the uveal tract of the eye is called uveal melanoma. The 
uvea is comprised of the iris, the ciliary body and the choroid. Uveal melanoma 
is a rare form of melanoma (less than 5% of all melanoma cases) but still the 
most common malignancy of the eye [139]. It most commonly develops in the 
choroid (90% of cases) and less frequently in the iris (4%) or ciliary body (6%) 
[140].  
1.4.1 Normal melanocytes 
Melanocytes in the iris determine the color of the eye, but the function of eye 
melanocytes is not fully understood. Aside from the iris, melanocytes are also 
found in the choroid (a vascularized layer situated between the retina and the 
sclera; supporting the eye with oxygen and nutrients) and the ciliary body 
(contain ciliary muscles determining the size of the pupil). Melanocytes in the 
uvea, alike other melanocytes in the body, are derived from neural crest and 
migrate to their final destination during embryonic development [141].  
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1.4.2 Epidemiology 
Uveal melanoma affects mainly the Caucasian population. Unlike skin 
melanoma, the incidence is stable and has not increased over recent years [142]. 
Uveal melanoma shows a south-to-north increase in prevalence in Europe [143]. 
The incidence in Sweden is 70-80 cases per year [144]. 
1.4.3 Etiology 
The cause of uveal melanoma is not fully understood. Unlike cutaneous 
melanoma, UV radiation could not be shown to be a risk factor for the 
development of uveal melanoma [145]. Welding has been revealed to be a risk 
factor for developing uveal melanoma [145]. 
The genetics of uveal melanoma are different from cutaneous melanoma 
(Figure 2), and BRAF and NRAS mutations are non-existent [146]. Instead, most 
uveal melanomas have mutations in Guanine Nucleotide-Binding Protein G(q) 
Subunit Alpha (GNAQ) [147] or Guanine Nucleotide-Binding Protein Subunit 
Alpha-11 (GNA11) [148]. Mutations in GNAQ or GNA11 occur in 83% of 
patients and are mutually exclusive. Less frequently, driver mutations are found 
in CYSLTR2 [149] or PLCB4 [150]. 
GNAQ and GNA11 are Gα GTPases which form complexes with Gβ and Gγ 
subunits and bind G-protein coupled receptors (GPCRs). In this state, the Gα is 
bound to a GDP and inactive. Upon activation, Gα exchanges the GDP to a GTP 
and dissociates from the complex. Mutations in uveal melanoma occur at R183 
or Q209 and leads to a decreased GTPase activity, preventing them from 
deactivation and rendering them constitutively active [147]. Activated Gα in turn 
activates phospholipase C-β (PLC-β) leading to hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol triphosphate (IP3) and 
diacylglycerol (DAG) [151]. DAG stimulate the mitogen activated protein 
kinase (MAPK) pathway by protein kinase C (PKC) whereas IP3 mediates Ca2+ 
signaling and is dephosphorylated into inositol monophosphate (IP1) [152]. 
MAPK activation drive proliferation and survival [146]. Activated GNAQ and 
GNA11 also stimulates the ADPribosylation factor 6 (ARF6)–TRIO–RHO/RAC 
pathway implicated in cytoskeletal organization, and yes-associated protein 65 
(YAP), also driving cancer initaiation and progression [153, 154]. Another 
common mutation in uveal melanoma is the BRCA1 Associated Protein-1 
(BAP1) tumor suppressor, which is inactivated in the majority of uveal 
melanomas [155]. This gene encodes a deubiquitinating enzyme that interacts 
with many proteins. Its inactivation occurs late and is associated with metastasis. 
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Based on genetics, uveal melanoma can be divided in two groups with 
diverse prognosis (class 1 and 2). Mutations in EIF1AX and SF3B1 are 
connected to low or intermediate risk of metastasis and to a better prognosis 
(class 1). Monosomy 3 and loss of the tumor supressor BAP1 are linked to high 
risk of metastasis and poor prognosis (class 2) [156]. Recently, we and others 
have also shown that additional changes affecting copy-numbers of certain gene 
segments (including the one encoding CDKN2A) can be seen in metastases as 
compared to the primary tumors [157, 158]. 
 
 
Figure 2. Signalling pathway alterations differ in cutaneous (CM, left in light gray box) and uveal 
melanoma (UM, right in yellow boxes). Frequent activating (gain-of-function) mutations are shown 
in pink and loss-of-function mutations are shown in green. In CM, mutations in NRAS and BRAF 
frequently occur and lead to MAP-kinase pathway activation (dark gray box), increased 
proliferation and survival and subsequent melanoma development. In UM, mutations most frequently 
occur in GNAQ and GNA11 activating the MAP-kinase pathway (dark gray box). Activated GNAQ 
and GNA11 also stimulate the ARF6–TRIO–RHO/RAC pathway implicated in cytoskeletal 
organization, as well as YAP, also driving cancer initaiation and progression. BAP1 is frequently 
lost in uveal melanoma which is strongly correlated to metastatic spread. Adapted and modified from 
[159]. 
1.4.4 Clinical classifications and prognosis 
Uveal melanoma most often affects the choroid, and less frequently the ciliary 
body or iris [140]. Iris melanomas show a better prognosis compared to those 
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arising in the ciliary body or choroid [160]. It is not clear, however, if this is due 
to easier detection and hence earlier treatment of iris melanomas compared to 
posterior uveal melanomas. 
The vast majority of uveal melanomas are detected before any signs of 
metastatic disease [161]. Nevertheless, 50% of patients will later present with 
metastases implicating a poor prognosis with a median survival of less than 6 
months [162, 163]. Uveal melanoma most frequently metastasizes to the liver 
(89% of patients), but also to other sites including lung (29%), bone (17%), skin 
(12%) and lymph node (11%) [161].    
1.4.5 Treatment options 
Primary uveal melanoma is treated with either brachytherapy or enucleation with 
very good local control [164]. Unfortunately, effective treatment of the primary 
tumor does not inhibit subsequent cancer progression, and around half of the 
patients diagnosed with uveal melanoma will later develop metastases [165]. 
Patients with metastatic uveal melanoma completely lack approved therapies 
today, because of poor effects of tested treatments so far [166, 167]. As a 
consequence, the prognosis for patients with uveal melanoma has not improved 
over the last decades [142]. There is therefore an unmet medical need for 
developing novel treatment strategies for these patients.  
1.4.5.1 Brachytherapy and enucleation 
Primary uveal melanoma was historically treated with enucleation. Of note, there 
have been concerns that enucleation may not just remove the primary tumor, but 
also enhance metastatic spread the years following enucleation [168]. Later there 
has been a shift toward eye-preserving treatments including local radiation to the 
eye, called brachytherapy. Brachytherapy with Rhutenium-106 or Iodine-125 is 
most commonly used, and was shown to be equally efficient as enucleation for 
control of the primary tumor and is therefore the preferred treatment used today 
[161]. 
Even though good local control is achieved in 96% of patients after treatment 
of the primary tumor [164], about 50% of patients will later present with 
metastatic disease. For patients with metastatic uveal melanoma, no approved 
therapies exist today. Most therapies tested have shown disappointingly limited 
efficacy, indicating that metastatic uveal melanoma is notoriously therapy-
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resistant. The coming sections will describe treatments that has been used in 
these patients, and their potential. 
1.4.5.2 Chemotherapy  
Systemic chemotherapy has been used in patients with metastases of uveal 
melanoma, but with no proof of a survival benefit [166, 167]. 
Because of the high frequency of liver metastases in patients with metastatic 
uveal melanoma, treatment can be targeted specifically to the liver. Intra-hepatic 
perfusion (IHP) with melphalan can be performed in patients with isolated 
hepatic metastases and increase survival (median survival 22 months) [169]. 
This and other loco-regional treatments, including liver resection [170] showed 
both feasibility and high response rates, but recurrence occurs in most patients 
indicating that they are not curative. 
1.4.5.3 Targeted therapy 
There are no approved targeted therapies for patients with uveal melanoma. The 
frequent mutations in GNAQ and GNA11 make these interesting targets for 
inhibitors, but unfortunately no such molecules has been developed [171]. 
However, activation of the MAPK pathway in uveal melanoma has implications 
for inhibitors targeting Mitogen-activated protein kinase kinase (MEK) and 
extracellular signal-regulated kinase (ERK). The MEK inhibitors Selumetinib 
[172] and Trametinib [173] have been tested in patients with uveal melanoma, 
but unfortunately, no overall survival benefit was achieved with this treatment. 
1.4.5.4 Immunotherapy 
Interestingly, lymphocyte infiltration has been correlated with poor prognosis in 
patients with uveal melanoma  [174, 175] as opposed to the opposite finding in 
most other cancer types [176]. TILs were mainly CD8+ T cells, and less CD4+ T 
cells, Tregs and B-cells [177]. Tumor infiltrating macrophages has also been 
correlated to poor prognosis in patients with uveal melanoma [178], and the 
main type of macrophages was found to be of the anti-inflammatory M2 
phenotype [179]. Furthermore, high expression of MHC I and II in uveal 
melanoma was also associated with poor survival [180, 181], which might 
indicate a role for NK cells in controlling metastatic spread. An inflammatory 
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phenotype in uveal melanoma, characterized by high expression of MHC I and II 
and infiltration of macrophages was associated with monosomy of chromosome 
3 [182], and hence highly correlated to metastatic progression [183].  
Immunotherapy with checkpoint inhibitors targeting CTLA4 and PD1 show 
great efficacy in patients with cutaneous melanoma [75, 78, 184], while these 
treatments are less promising in uveal melanoma patients [185, 186]. It has been 
suggested that uveal melanoma is a non-immunogenic cancer due to its origin in 
the eye which is an immune-privileged site [187]. Indeed, uveal melanomas have 
a low mutational burden [150, 188], especially compared to cutaneous 
melanoma which is one of the most highy mutated cancers [130]. A low 
mutational burden indicates a lack of immunogeneity [189]. Nevertheless, 
studies have shown that there is an immunogenic subset in uveal melanoma 
[190].  
Another immunotherapy that was efficatious in 50% of patients with 
cutaneous melanoma is adoptive T cell transfer (ACT) with tumor infiltrating 
lymphocytes (TILs) [85, 86, 138]. ACT has also been tested in uveal melanoma 
in a clinical trial [191]. Response rates of 35% were reported, demonstrating 
potential for T cell-based immunotherapy in uveal melanoma. However, only 1 
patient out of 21 reached complete and long-term response (>20 months), 
indicating a need for improving response frequency and durability. 
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2. Aims 
The overall aim of this thesis was to use mouse models to study novel 
therapeutic strategies to treat metastatic melanoma. Specifically, the aims of the 
papers incuded in this thesis were: 
 
Paper I  
To create novel mouse models to study immunotherapy in melanoma  
 
Paper II 
To use these models to find novel treatment strategies for melanoma  
 
Paper III 
To conduct the preclinical experiments needed to enable a clinical trial  
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3. Methods  
3.1 Preclinical research 
3.1.1. In vitro models 
Cancer cell lines have been used extensively in pre-clinical cancer research 
[192]. They are cheap to use compared to other preclinical models, and provide a 
fast and easy-to-use system, especially for screening of novel drugs or 
combinational therapies. Cell lines can also be grown in immune-compromised 
mice as cell-line derived xenografts [193]. The problem with cell lines is that 
they usually do not represent the complex reality in tumors very well, because of 
the different selection pressure on cells in vitro compared to in vivo [194, 195]. 
Hence, findings made using cancer cell lines should also be validated in more 
accurate in vivo models. 
There are many commersially available cell lines from metastatic cutaneous 
melanoma. Cell lines from metastatic uveal melanoma have been more difficult 
to obtain. Instead, cell lines from primary tumors (grown in vitro or as PDXes) 
have been commonly used in pre-clinical research of uveal melanoma. 
3.1.2. In vivo models 
Many different model organisms are used to study cancer, including (but not 
limited to) yeast, fruit flies, zebrafish, mice, rats and dogs. 
The mouse as a model organism has many advantages. It has a relatively 
short reproduction time and is easily housed. There is a high similarity between 
mouse and human genetics (80% of mouse genes have human orthologues) 
[196]. Furthermore, there are many well-characterized mouse models already 
developed for cancer research [197]. Genetically engineered mouse models 
(GEMMs) generally model disease progression more accurately compared to in 
vitro models [197]. On the other hand, GEMMs cannot recapitulate the 
heterogenous nature in human cancer patients. To study these intra-patient 
characteristics, many different syngenic transplant models of spontaneous or 
chemically induced tumor models can be used. An alternative is patient-derived 
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xenograft mouse models, where human tumors are engrafted to immune-
compromised mice. 
3.1.2.1 GEMMs 
Mice can be genetically altered to spontaneously develop cancer, called 
genetically engineered mouse models (GEMMs). In these models, disease 
progression can be studied (from spontaneous tumor formation to metastatic 
spread) in an in vivo setting. 
Several GEMMs have been established for cutaneous melanoma [198]. For 
example, activation oncogenic Braf V600E together with Pten loss generate 
cutaneous metastatic melanoma in mice [199]. There are two uveal melanoma 
GEMM model, driven by inducuble oncogenic GNAQ Q209L [200] or GNA11 
Q209L [201]. In these models, mice develop neoplasms of the uvea and central 
nervous system as well as pigment anomalies in skin and impaired hearing and 
balance. Loss of BAP1 leads to acceleration, akin to the human situation [201]. 
GEMMs can be used for studying spontaneous cancer development in mice, 
and accurately model interactions between the tumor and microenvironment, 
including interactions with the immune system. The limitations of GEMMs 
include differences in human and mouse biology, for example treatments tested 
in research using mice might not be directly applicable for human use. 
3.1.2.2 PDX models 
Patient derived xenograft (PDX) models are mice with human tumor transplants. 
In order for successful engraftment of human tumors, mice are altered to be 
immunocompromised (they lack a functional immune system). There are 
different strains of immunocompromised mice. Nude mice lack thymic tissue 
and were the first immunocompromised mice successfully used to transplant 
human tumors [202]. The lack of thymus in nude mice results in the abcense of 
T lymphocytes and alterations in B lymphocyte function. NOD/SCID mice 
harbor defects in many components of the immune system, they completely lack 
functional T and B lymphocytes and have reduced macrophage and NK cell 
function [203]. NOD/SCID/interleukin-2Rγ mutant mice (called NOG [204] or 
NSG [205]) are further immunocompromised and are currently the models with 
the highest engraftment rate of human tumors. NOG/NSG mice completely lack 
functional NK cells as well as T and B lymphocytes. 
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PDX mouse models can be readily established for cutaneous melanoma [206] 
and especially well in NOG mice [207, 208]. In general, metastatic cutaneous 
melanoma PDXes have a take-rate of about 90% and can be established in a few 
months time. Metastatic uveal melanoma has a lower take rate in NOG mice and 
generally takes longer to develop. Liver metastases have a take rate of about 
10% and take 6-12 months to develop. Cutaneous metastases, on the other hand, 
behave more like cutaneous melanoma with good take rate (Figure 3). 
PDXs can accurately model human tumors, including intra-patient 
heterogeneity, and correlate to therapeutic responses in patients [208-210]. PDX 
models also enable testing of human specific reagents directly in the mouse 
model. An important disadvantage of PDX models is the challenge to study 
interactions of tumor and the microenvironment, especially since the mice are 
immune-compromised and lack a functional immune system.  
Recently, efforts have been made to create so called immune-humanized 
mice, were human immune cells are grafted in immune-compromised mice 
[211]. These models often depend on engraftment of human peripheral blood 
leukocytes (PBLs) or hematopoetic stem cells (HSCs). These models develop a 
subset of human immune systems, but there is a challenge of immune cell 
education in the mice. Also, these mice frequently develop symptoms of Graft 
versus Host disease – posing a challenge for using these models [212].  
3.2 Clinical trials 
Ultimately, the goal of pre-clinical cancer research is to find novel therapeutic 
approaches to benefit cancer patients. In order for a treatment strategy to be 
approved for use in patients, it has to be tested in phase I through III clinical 
trials. Phase I trials focus on safety, and usually starts with a low dose and 
treatment of a small number of patients (one at a time). Phase IV trials are 
conducted with approved therapies on large cohorts of patients, in order to better 
understand efficacy and safety of the treatment. In order to reach the next level 
of clinical testing, a benefit for the patients needs to be established. Most anti-
cancer drugs fail to prove efficacy in clinical trials, leading to clinical approval 
in only about 10% [213]. The low success rate in clinical trials points to the 
importance of using accurate pre-clinical models in the search for novel cancer 
treatments. 
For metastatic cutaneous melanoma, several treatment strategies have already 
been approved for patient use, including targeted therapies inhibiting BRAF and 
MEK as well as immunotherapies blocking checkpoint proteins CTLA4 and 
PD1. For metastatic uveal melanoma on the other hand, no potential treatment 
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strategy has so far reached clinical approval because of failure to prove survival 
benefit. A rare disease such as uveal melanoma also poses a challenge for 
conveying clinical trials, because of the limited number of available patients. 
 
 
Figure 3. Generation of patient-derived xenograft (PDX) models of cutaneous melanoma (CM) and 
uveal melanoma (UM). A) Number of tumors from cutaneous melanoma (CM, blue) and uveal 
melanoma (UM, red) established at different timepoints after engraftment in NOG mice (days). 
Asterisks above 3 UM samples indicates subcutaneous metastases, the other 3 UM are liver 
metastases. B) Number of tumors successfully engrafted on mice (blue) and tumors that were not 
(red) between 2012 and 2017 from cutaneous melanoma (CM) and uveal melanoma (UM). Out of the 
6 uveal samples that were successfully engrafted on mice, 3 were subcutaneous metastases and 3 
were liver metastases.    
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4. Results 
Paper I 
Patient-derived xenograft (PDX) mouse models have been used extensively in 
pre-clinical cancer research, and have been shown to mimic therapeutic effects 
in patients [209, 210]. In melanoma specifically, PDX models can be readliy 
established [206], and have been shown to accurately model the disease and even 
develop fast enough to guide treatment decisions [208]. A requirement for 
human tumors to engraft in mice is that the mice are immune-compromized, in 
order for the graft not to be rejected by the host immune system. With recent 
advances in treatment of melanoma using immune-therapies including antibody-
based and cell-based techniques, classical PDX models are no longer good pre-
clinical tools simply because the mice lack a functional immune system, making 
studies of immunotherapies impossible. 
The aim of this paper was to create immune-humanized mouse models of 
malignant melanoma, to model adoptive T cell transfer (ACT) in PDX mice. In 
order to meet this goal, we created a model called PDX version 2 (PDXv2), 
where immune cells (tumor-infiltrating lymphocytes; TILs) and tumor cells from 
the same patient with malignant melanoma were grafted in the same mouse. 
Etsablishing the PDXv2 model 
We aquired TILs and tumor cells from malignant melanoma patients enrolled in 
a clinical trial studying ACT in Herlev, Denmark [138]. The tumor cells were 
transplanted to NOG mice while TILs simultaneously were isolated from tumor 
pieces and further expanded to large numbers in vitro using a rapid expansion 
protocol (REP). Subsequently, TILs were adoptively transferred to NOG mice 
carrying autologous tumors.   
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T cells can home to, but not kill, tumors in wt NOG mice 
In vitro studies were conducted, assessing tumor cell viability and TIL IFN-γ 
production when co-culturing autologous tumor cells and TILs in vitro from a 
patient with malignant melanoma (MM33). The tumor cells could be readily 
killed by T cells in vitro, accompanied with high IFN-γ production by the T 
cells.  
We next tested ACT treatment in NOG mice, by engrafting MM33 tumor 
cells and infusing autologous TILs consecutively. Mice were treated with hIL-2 
(45 000 IU on the day of TIL infusion and the next two days, and then biweekly 
for two weeks) to resemble the protocol used in patients undergoing ACT in the 
clinic. Although using a tumor sample which was effectively killed by 
autologous TILs in vitro, no effect of ACT could be achieved in NOG mice. 
To investigate wheather the TILs were able to reach the tumor in NOG mice, 
tumors from vehicle or TIL treated mice were sacrificed, and the tumors 
analyzed with immunohistochemistry and flow cytometry. The IHC revealed T-
cells in tumors treated with TILs as assessed by positive staining of human CD3. 
Furthermore, an upregulation of the PD1/PDL1 axis was observed in TILs after 
tumor encounter, as revealed by PDL1 upregulation in TIL treated tumors by 
IHC as well as an increased PD1 expression in TILs from the tumors compared 
to the infusion product. This fact encouraged subsequent treatment of the mice 
with the PD1 inhibitor pembroluzimab, but still without resulting in tumor 
regressions.  
In order to rule out the possibility that the MM33 TILs were non-functional 
in vivo for any unknown reason, additional experiments were performed with 4 
samples which were known from the clinical trial to be one complete responder 
to ACT (MM11), one partial responder (MM24) and two non-responders 
(MM29 and MM46). Mice were transplanted with tumor cells and subsequently 
treated with TILs with or without the addition of pembrolizumab. There was a 
slight decrease in tumor growth in MM46 treated with TILs and pembrolizumab, 
as well as in MM24 treated with TILs (with and without pembrolizumab). 
However, still no tumor regressions were achieved.   
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hIL-2 transgene expression enables tumor eradication in NOG mice 
We hypothesized that some factor was missing in our mouse model, in order for 
the T cells to be able to kill the tumor cells. A potential reason for the lack of 
effect of ACT in NOG mice included additional tumor evasion mechanisms 
aside from PD1/PDL1 engagement and insufficient viability of TILs in vivo. 
One important factor for T cell viability and expansion is IL-2. Potentially, the 
half-life of IL-2 was too short or the dosing scheme used was insufficient in 
mice. We found that IL-2 plasma levels in mice peaked 2 hours after injection 
and was almost completely vanished after 6 hours. In order to circumvent this 
problem, we purchased NOG mice transgenic for human IL-2 (hIL2-NOG; 
Taconic). The hIL2-NOG mice had various levels of IL-2 in plasma ranging 
from 0 to 8 ng/ml.  
We found that mice with >2 ng/ml IL-2 in plasma could support survival and 
expansion of TILs in mice for more than 6 weeks. TILs were shown to 
selectively home to the tumor site in IL-2 transgenic mice. When repeating 
adoptive T cell transfer in IL-2 mice carrying MM33 tumors, treatment with 
TILs and Pembrolizumab could eradicate the tumors. Additional experiments 
showed that TILs alone could eliminate the tumors in MM33, and no additional 
benefit could be shown with Pembrolizumab treatment. 
PDXv2 accurately model ACT in patients with malignant melanoma 
Additional experiments were performed with samples from patients in the 
clinical trial testing ACT in IL-2 transgenic mice. 3 samples were responders to 
ACT in the clinic (MM11, MM05 and MM24) and 3 samples were non-
responders to ACT (MM29, MM46 and MM04). The samples from ACT 
responders in the clinic were able to eradicate autologous tumors in IL-2 
transgenic NOG mice, while samples from non-responding patients did not 
cause tumor-shrinkage in mice.  
In order to investigate whether TILs could also eradicate melanoma in other 
sites than the skin, MM33 engrafted mice were treated with surgery to remove 
the primary tumor and allow for metastatic spread in the same mouse. We found 
that metastatic spread to lymph nodes as well as the liver could be targeted 
effectively with TILs in PDXv2 in 3 out of 4 mice. 
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Paper II 
The next step after creating PDXv2 (Paper I), was to use this model in order to 
study immunotherapy in melanoma. In the mouse model, just as in the malignant 
melanoma patients in the clinical trial, not all tumors were responders to ACT 
with TILs. We set out to find a way to treat non-responders of ACT in this 
model. One approach to overcome several immune-evasion strategies used by 
tumors, including downregulation of antigen presentation, lack of suitable 
neoantigens and expression of inhibitory receptors is to use CAR-T cells. CAR-
T cells are genetically manipulated to express a chimeric receptor (CAR) able to 
recognize specific surface proteins on tumor cells. This recognition is 
independent of antigen presentation and circumvents normal regulatory 
mechanisms inhibiting T cell function. 
CAR-T cells have been very useful in the treatment of B-cell malignancies 
[93, 94], and CD19 targeting CAR-T treatments have already been approved for 
use in patients. CAR-T therapies have been less successful in pre-clinical models 
of solid tumors, and consequently no CAR-T therapy has been approved for use 
in solid cancers [103]. In this paper, we tested CAR-T cell therapy in PDXv2.  
Expression of HER2 in melanoma 
In order to predict useful CAR-T targets, we used The Cancer Genome Atlas 
(TCGA) to look at expression of genes encoding published CAR-T targets. 
Among the available targets HER2 (ERBB2), CD20 (MS4A1), CD19, VEGF 
(KDR), Glypican-3 (GPC3), CD133 (PROM1) and EpCAM, HER2 was the 
most highly expressed both in cutaneous and uveal melanoma. We also found 
HER2 to be expressed in tumor samples from patients and in PDX models from 
mice as well as in commersially available melanoma cell lines. HER2 protein 
expression could also be detected in cutaneous and uveal melanoma PDX tumors 
from mice using immunohistochemistry. 
We obtained HER2 CAR-T cells (ProMab) and tested them in vitro in two 
melanoma cell lines, one with high HER2 expression (HS695) and one with low 
expression (SK-MEL-1). The cell line with high HER2 expression was more 
sensitive to CAR-T cell degranulation and CAR-T cell killing in vitro compared 
to the HER2 low cell line, suggesting target specific killing. 
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HER2 CAR-T cells kill melanoma cells in vitro and are target-specific 
To test the killing capacity in vitro of the HER2 CAR-T cells in patient-derived 
cells from malignant melanoma and cell lines from uveal melanoma. We found 
that the CAR-T cells could kill both malignant melanoma cells and uveal 
melanoma cell lines, assesed by decreased viability of cancer cells and CAR-T 
mediated degranulation and IFN-γ production.  
In order to validate the specificity of the CAR-T cells, we used CRISPR/Cas9 
technology to disrupt HER2 genetically in cutaneous and uveal melanoma cells. 
HER2 negative cells were unresponsive to CAR-T cell killing, and did not 
provoke degranulation and IFN-γ production by the CAR-T cells, indicating that 
the CAR-T cells were target-specific. 
ACT-resistant cutaneous and uveal melanoma can be eradicated by 
HER2 CAR-T cells in PDXv2 
We next treated NOG and hIL2 NOG mice carrying cutaneous melanoma 
PDXes with CAR-T cells. We found that all 5 tested samples were responsive to 
CAR-T cell killing in vivo, but only in hIL2-transgenic NOG mice and not in wt 
NOG mice. Importantly, treatment with CAR-T cells was effective irrespectively 
of whether the samples were from responders or non-responders to ACT with 
autologous TILs. Furthermore, CAR-T cells could eradicate one cell line-derived 
xenograft and one PDX of uveal melanoma in hIL2 mice.    
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Paper III 
Encouraged by the finding that HER2 CAR-T cells were able to eradicate both 
malignant melanomas that were non-responders to ACT and uveal melanomas 
(Paper II), we wanted to further explore the possibilities of CAR-T treatment and 
facilitate the translation into clinical testing.  
Current CAR-T therapies use T cells from peripheral blood as basis for CAR-
T cell production (including the HER2 CAR-T cells used in Paper II; ProMab). 
We hypothesized that it would be possible to use patient’s autologous TILs as 
CAR-T substrate instead of blood T cells. At least theoretically, this strategy 
could combine the advantages of both ACT and CAR-T therapy in the same 
treatment. ACT with TILs has the advantage that most TILs retain their ability to 
home to the tumor even after in vitro expansion [214]. TILs are also trained T 
cells and might therefore be safer to use in patients compared to blood-derived T 
cells. Moreover, some TILs might recognize the tumor via their intrinsic T-cell 
receptor (TCR). On top of this, the added CAR-receptor can recognize proteins 
on the tumor surface independent of antigen presentation, and can elicit effective 
killing of less immunogenic tumors, including ACT non-responding melanomas 
and uveal melanomas (Paper II). In this paper, we developed a novel approach to 
treat melanoma, by equipping patient-derived TILs with improved means to 
target autologous tumors. 
TILs can be manipulated in vitro to express a CAR construct 
With the aim to equip TILs with a HER2 CAR receptor, we used the same 
lentiviral vector as used in the commercial production of the HER2 CAR-T cells 
(Promab, Paper II). TILs could be successfully transduced before rapid 
expansion (REP) or transduced on day 1 and 2 of the REP. The CAR construct 
was detected in CAR transduced TILs (CAR-TILs) at the end of expansion by 
qPCR and flow cytometry. Lentiviral transduction enables the CAR construct to 
be incorporated into the genome at random, resulting in CAR-TILs retaining 
their normal TCR allowing dual tumor cell targeting.  
CAR-TILs can kill melanoma cells independent of MHC I 
presentation 
As a proof-of-concept for CAR-mediated killing, CRISPR/Cas9 technology was 
used to disrupt the gene encoding β-2-Microglobulin, B2M. B2M is part of the 
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MHC I complex and required for assembly of MHC I on the cell surface. Indeed, 
B2M knockout MM33 tumor cells were completely insensitive to TIL mediated 
killing (assessed by tumor cell viability and TIL degranulation), while the 
parental MM33 cells are sensitive. Intriguingly, MM33 CAR-TILs were able to 
degranulate in response to and kill B2M negative MM33 tumor cells both in 
vitro and in vivo, proving that the antigen presentation dependency for TIL 
mediated killing was overcome by the CAR-receptor. 
CAR-TILs and TILs are equally efficient to treat ACT responders 
To compare the efficacy of CAR-TILs and TILs in ACT-responsive samples, 
TILs and CAR-TILs were produced as described previously, and used to treat 
IL-2 transgenic mice with autologous tumors. We found that TILs and CAR-
TILs were equally efficient to treat one cutaneous and one uveal melanoma 
sample that responded to autologous TILs. This indicated that CAR-TIL 
production does not impact negatively on TCR mediated tumor killing. 
Therefore, CAR-TIL treatment can be a conceivable treatment strategy for 
patients, irrespecitive if they would respond or not to regular ACT treatment. 
Another cutaneous melanoma sample (FOHO) was completely refractory both to 
autologous TILs and to CAR-TILs, indicating that not all immune evasion 
strategies used by melanoma can be overcome by CAR mediated tumor 
recognition. Other immune evasion strategies might be responsible for the lack 
of response, including the ability of tumor cells to undergo T-cell mediated 
apoptosis or factors in the tumor microenvironment suppressing T cell function. 
Automated production of CAR-TILs facilitates clinical translation 
The requirements for sterility and conformity during production of advanced 
therapy medicinal products (ATMPs) for patient use are of utmost priority. In 
order to simplify and ensure safety during CAR-TIL production, we used a 
bioreactor (CliniMACS Prodigy; Miltenyi) for expansion and transduction of 
CAR-TILs. The bioreactor is a closed system ensuring minimal risk of 
contamination during production. Also, the automated protocol used for all 
processes during expansion including transduction, washing of cells, media 
exchange etc reduces variations during production. The process used to produce 
CAR-TILs must also include only materials approved for clinical use, and all 
processes involved in the production must be performed according to good 
manufacturing practice (GMP). GMP requirements include all handling of the 
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product to be performed in controlled environments, called cleanrooms, and by 
educated personel. Taken together, all of these requirements necessitate changes 
to the protocol and materials used for CAR-TIL production for clinical use 
compared to research use.  
In order to facilitate translation of the CAR-TIL treatment strategy to reach 
acceptance for clinical testing, we developed an automated protocol for CAR-
TIL production including expansion in a bioreactor. The protocol was validated 
by testing the functionality of cells produced with the automated protocol 
compared to cells produced with the standard (manual) protocol in PDXv2. First, 
TILs were produced from melanoma sample M160811 with both protocols, and 
then used to treat IL-2 transgenic mice carrying autologous tumors. TILs 
produced with both protocols caused tumor regressions in all mice. Next, CAR-
TILs were produced from MM33 using the automated protocol and compared to 
MM33 CAR-TILs produced with the manual protocol by injection to IL-2 
transgenic mice carrying MM33 B2M KO tumors. CAR-TILs produced with 
both protocols included a population of CAR positive cells (14% with the 
manual protocol and 11% with the automated protocol), and supported complete 
tumor rejections in mice carrying autolougus B2M KO tumors. 
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5. Discussion 
Paper I 
PDXv2 is, to our knowledge, the first PDX mouse model to achieve complete 
responses of human tumor cells by autologous immune cells. Importantly, this 
model could accurately recapitulate responses to ACT in patients in a clinical 
trial, confirming usability of this model in pre-clinical research.  
Other immune-humanized mouse models have been previously developed, 
using either hematopoetic stem cells or peripheral blood mononuclear cells 
(PBMCs) [211]. These models frequently develop symptoms of Graft versus 
Host disease (GvH) [212]. In contrast, no GvH disease was detected in the mice 
treated with TILs. Instead, IL-2 transgenic mice treated with TILs often 
presented with enlarged spleens and sometimes developed lympho-proliferative 
disease with enlarged lymph nodes and high blood cell count. These side-effects 
were generally late events, appearing after TILs had completely eradicated the 
tumors (in the case for ACT responding samples). It is possible that TILs are less 
toxic to mice compared to less educated T cells, explaining the relatively mild 
side-effects in PDXv2. 
We found that human IL-2 is required for ACT in mice, and IL-2 transgenic 
mice facilitate experiments. The dependency of IL-2 in this model indicates the 
importance of IL-2 treatment to achieve efficacy of ACT. However, high dose 
IL-2 can lead to serious side effects in patients, stressing the importance of 
accurate IL-2 dosing. Lower but continuous IL-2 dosing was shown to support 
efficacy of TILs in a clinical trial [215]. 
Interestingly, PD1 inhibition could not replace IL-2 in NOG mice. This could 
be because a missing component – dendritic cells - are not present in the NOG 
mice [216]. Furthermore, PD1 inhibition (pembrolizumab) impose no additional 
effect in this model, probably because IL-2 overrides the PD1/PDL1 axis, as was 
previously reported [217]. Therefore, PDXv2 might not be the optimal model to 
study PD1 blockade. Potentially, checkpoint blockade using other antibodies 
could be studied in the PDXv2 mouse model.   
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Paper II 
HER2 is expressed in cutanous and uveal melanoma, and represents a novel 
CAR target for melanoma. HER2 expression was equally high as in sarcoma, 
another disease where HER2 targeted CAR-T therapy has been tested [100], but 
not as high as in HER2 overexpressing breast cancer. We show that HER2 CAR-
T cells can kill ACT refractory cutaneous melanoma and uveal melanoma in 
vitro and in IL-2 transgenic NOG mice. HER2 as a target for cutaneous and 
uveal melanoma has not previously been studied, representing an interesting 
possibility for developing novel therapeutic strategies for melanoma patients that 
do not benefit from available therapies, and uveal melanoma patients with no 
current available therapies. 
 Human IL-2 is required for tumor eradication in mice, and lack of IL-2 is a 
potential reason for poorer responses to CAR-T therapies in solid tumors 
compared to hematologic malignancies. Possibly, models like PDXv2 can 
facilitate pre-clinical studies of CAR-T therapies. 
In the immune-humanized mouse model used here, IL-2 transgenic NOG 
mice are used to engraft human tumor cells and human CAR-T cells. This 
system is informative for showing interactions between CAR-T cells and the 
tumor, but cannot recapitulate the complexity of a normal immune system. 
Limitations to this type of immune-humanized mouse model include difficulties 
to study toxicities in this model (for example on-target off-tumor effects), 
because normal tissues in the model are mouse origin. It is also difficult to use 
this model to study persistence of T cells because of the constitutive expression 
of IL-2 driving T cell proliferation. It might also be of interest to develop a 
mouse model with inducible expression of IL-2 in order to facilitate studies on 
aspects including long-term treatment effects after T cells are “turned 
off/disappear” after tumor eradication. Hence, efficacy of the treatment can be 
well modeled in the PDXv2 mouse model, while other characteristics such as 
safety and durability are more difficult to assess. These factors are in general 
difficult to study in cancer models, and might not be accurately measured 
anywhere else than in a clinical trial.  
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Paper III 
Challenges for immunotherapies include how to target non-immunogenic 
tumors, for example those with low mutational load (lack of neoantigens) or 
immune evasion strategies including downregulation of the antigen presentation 
pathway. Cutaneous melanoma should be an optimal disease for 
immunotherapies, because of the high mutational load, and indeed 
immunotherapies including checkpoint blockade and ACT show great efficacy in 
this patient group. Still, not all patients with cutanoues melanoma will benefit 
from available immunotherapies. Uveal melanoma is a less immunogenic type of 
melanoma compared to cutaneous melanoma, with lower mutational load [150, 
188] and disappointingly poor effects were achieved with checkpoint blockade 
in these patients [185, 186]. ACT showed some effect in uveal melanoma, but 
markedly less compared to cutaneous melanoma [191]. Importantly, metastatic 
uveal melanoma completely lacks approved therapies today, stressing the urgent 
need for improving therapeutic strategies for this patient group. 
Here we present a novel approach to target melanoma by equipping TILs 
with a CAR targeting HER2, called CAR-TILs. This approach could enhance 
TIL killing capacity of autologous tumors, circumventing poor efficacy of some 
TILs. CAR-TILs were able to target autologous tumor cells in a completely 
MHCI independent manner, since CRISPR/Cas9 disruption of B2M in 
melanoma cells (B2M KO) were resistant to TILs but sensitive to CAR-TILs. 
This is highly relevant since loss or downregulation of B2M in melanoma has 
been correlated to resistance in melanoma patients treated with different 
immunotherapies, including ACT [218] and PD1 inhibition [219]. The fact that 
B2M KO cells are sensitive to CAR-TILs shows that CAR-mediated killing is 
possible, even in the absence of MHC-TCR interactions. However, dual 
targeting in CAR-TILs inflicts an additional challenge to determine if killing is 
TCR or CAR mediated (or both). In one sample refractory to ACT with 
autologous TILs (FOHO), CAR-TILs too did not affect tumor growth, indicating 
that additional immune evasion strategies can be employed by tumor cells 
rendering them insensitive to CAR-TIL mediated killing. Since this sample 
express HER2, the unresponsiveness might be due to other factors besides T cell 
recognition. Potential reasons include tumor-intrinsic resistance to T cell killing 
or other factors in the tumor microenvironment supressing T cell function. 
The immune-humanized PDX model used here (PDXv2) was previously 
shown to accurately model ACT (Paper I), indicating a usefulness in this model 
for testing novel treatment strategies. However, it is difficult to study off-target 
and on-target off-tumor effects in this model, simply because normal tissues in 
the model are of mouse origin. Mouse HER2 is not completely identical to 
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human HER2 (identity of 86%), making it impossible to accurately assess safety 
in this model. One phase 1/11 study used HER2 CAR-T cells in patients with 
HER2 positive sarcoma, and found that this treatment was safe, although with 
limited clinical responses [100]. However, when using the same treatment but in 
combination with a conditioning chemotherapy, responses could be achieved in 
patients with sarcoma (clinical trial ref NCT00902044, abstract nr LB-147/4 
presented on AACR, 2019). HER2 CAR-T cells have also been evaluated in 
phase I trials of  HER2 positive glioblastoma [101] as well as biliary tract 
cancers and pancreatic cancers [102], and both trials found that this treatment 
was safe and indicated some clinical activity. In an early case-study, one patient 
with colon cancer was treated with a dose of HER2 CAR-T cells that is much 
higher than used nowadays, resulting in that the patient suffered from pulmonary 
distress leading to death [220]. This event clearly underlines the danger in using 
novel CAR T cells at high doses, without doing a proper dose-escalation study, 
starting with low doses and only increasing the dose after safety could be 
proven. The HER2 CAR-T construct used in the current study has not been 
previously tested in patients. 
Automated production of TILs and CAR-TILs using a bioreactor 
(CliniMACS Prodigy, Miltenyi) facilitates clinical translation. It also minimizes 
the risk of contaminations and operator-dependent differences between 
consecutive samples. Reassuringly, TILs and CAR-TILs produced in an 
automated fashion using the bioreactor was equally efficient in eradicating 
autologous tumors in mice as compared to cells produced with the standard 
protocol. Taken together, these findings potentiate future clinical testing of 
HER2 CAR-TIL treatment in patients with cutaneous and uveal melanoma that 
did not benefit of currently available therapies. 
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6. Conclusion and future 
perspective 
We have developed an immune-humanized mouse model called PDXv2, where 
human tumor xenografts and human T cells are engrafted in the same IL2 
transgenic NOG mouse. This model could accurately model ACT with 
autologous TILs in cutaneous melanoma, since effects in the mouse model 
correlated with clinical responses in the corresponding patients in a clinical trial. 
PDXv2 could also be used to discover a novel and efficatious CAR-T target 
for melanoma (HER2). HER2 CAR-T treatment was capable of eradicating both 
ACT resistant cutaneous and uveal melanoma xenografts in IL-2 transgenic 
NOG mice, proving for the first time that complete regressions of solid tumors 
can be achieved by CAR-T treatment in mice.          
Finally, PDXv2 was used to validate a novel immunotherapeutic approach to 
overcome resistance to immunotherapy in melanoma, called CAR-TIL 
treatment. By equipping autologous TILs with a HER2 CAR-construct, TILs 
could kill melanoma cells independent of antigen presentation and enabled 
killing of an ACT non-responding sample. Furthermore, CAR-TILs could be 
produced in an automated fashion facilitating the translation from pre-clinical 
findings into clinical testing. A clinical trial is warranted to learn the true 
potential for CAR-TIL treatment in patients with metastatic melanoma. 
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